What are the complications of nonmyeloablative allogeneic stem cell transplantation (ASCT) for the treatment of renal cell carcinoma (RCC)?

Updated: Feb 19, 2021
  • Author: Kush Sachdeva, MD; Chief Editor: E Jason Abel, MD  more...
  • Print

Two patients died of transplantation-related causes, and eight died from progressive disease. In 10 patients (53%), metastatic disease regressed; three patients had a complete response, and seven had a partial response. [71] The durations of these responses continue to be assessed. Further trials are needed to confirm these findings and to evaluate long-term benefits.

Did this answer your question?
Additional feedback? (Optional)
Thank you for your feedback!